Parp Inhibitors Market Overview
The PARP inhibitors market is estimated to be worth $8 billion in 2030 and is expected to grow at CAGR of 18% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. In the US, 0.6 million deaths (https://www.cancer.gov/about-cancer/understanding/statistics) were reported to have been caused due to cancer in 2018 alone. Further, according to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. It is worth mentioning that in the past five years, the United States Food and Drug Administration (USFDA) (https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications) has approved more than 100 drugs for the treatment of different types of cancer. However, as the growing global population is gradually being exposed to a growing list of risk factors and cancer causing agents, there is a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition. Over time, conventional treatment options, such as chemotherapy, surgery and radiation therapy, have shown limited efficacy in treating late-stage cancers. In addition, the non-specific and highly toxic nature of these therapies have severe detrimental effects on patients’ quality of life.
Defects in deoxyribonucleic acid (DNA) repair have been shown to be one of the primary causes of cancer. Moreover, tumor cells that are characterized by impaired DNA repair pathways typically become reliant on alternative DNA repair pathways for survival. This phenomenon is commonly referred to as oncogene addiction. Inhibitors of such compensatory repair pathways have the potential to sensitize cancer cells to DNA damaging agents and other therapeutic regimens. On the other hand, the simultaneous inactivation of certain pairs of genes have been shown to cause cell death. This phenomenon is known as synthetic lethality. In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques (https://www.ncbi.nlm.nih.gov/pubmed/28523286), have led to the identification of a number of synthetically lethal gene pairs.
Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality. Further, several such parp inhibitors drugs are being investigated for the treatment of a myriad of advanced oncological and non-oncological indications. A number of companies are engaged in PARP inhibitors market; moreover, both venture capital (VC) firms and government bodies are actively funding such research initiatives.
Key Companies in PARP Inhibitors Market
Examples of key companies engaged in PARP inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, BeiGene, Clovis Oncology, GlaxoSmithKline, Pfizer and AtlasMedx. This market report includes an easily searchable excel database of all the companies providing PARP inhibitors and other synthetic lethality based drugs, worldwide.
Scope of the Report
The ‘PARP Inhibitors Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways’ market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunities of the PARP inhibitors market. It features an in-depth analysis, highlighting the capabilities of various companies engaged in PARP inhibitors market.
In addition to other elements, the market research report includes:
- A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration. In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.
- Detailed profiles of large players that are engaged in the development of parp inhibitors drugs (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and an excerpt on its developmental history. In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of the executive team), recent developments, along with descriptions of their synthetic lethality-based drug candidates.
- An analysis of the prevalent and emerging trends in PARP inhibitors market, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.
- An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment. It includes an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor).
- An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts). In addition, this analysis features a multi-dimensional bubble chart analysis to assess the relative level of expertise of the key authors / researchers based on the number of publications, citation count and research gate score.
- An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers. It also features a detailed analysis on most popular synlet targets and target indications, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of synlet targets and number of indications under study.
- An analysis of the investments made into companies that have proprietary parp inhibitors drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.
- An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated). Further, it highlights the long-term opportunities (for drug developers) associated with individual targets, based on their popularity across different portals.
- An analysis of the role of innovative companion diagnostics in synthetic lethality on the basis of several parameters, such as synlet target, drug candidate(s) being investigated, target biomarker(s), target disease indication(s) and assay technique used. It also includes case studies, highlighting those companion diagnostic tests that are available and are being used to evaluate the therapeutic efficiency of approved PARP inhibitors using the principle of synthetic lethality.
The key objective of PARP inhibitors market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics and future opportunity for PARP inhibitors market during the forecast period. Based on multiple parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the marketed and late stage parp inhibitors drugs and the likely selling price, we have provided informed estimates on the evolution of the market over the forecast period 2019-2030. The market report includes potential sales forecast of drugs that are currently marketed or are in late stages of development (phase II and above). The market report also features the likely distribution of the current and forecasted opportunity across [A] type of molecules (small molecule and biologic), [B] different target indications (breast cancer, cervical / anogenital cancer, diabetic macular edema, gastric cancer, lung cancer, ovarian cancer and renal cell cancer), [C] synlet targets (APE1 / REF-1, CHK1, GLS1, PARP, Polθ, and WEE1), [D] route of administration (oral and intravenous), and [E] key geographical regions (North America, EU5, Asia-Pacific and Rest of the World). To account for the uncertainties associated with the growth of parp inhibitors drugs market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in this market research were also influenced by discussions conducted with multiple stakeholders in PARP inhibitors market. The market research report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):
- Simon Boulton (Vice President, Science Strategy, Artios Pharma)
- Yi Xu (Associate Director, Business Development, IMPACT Therapeutics)
- Norbert Perrimon (Professor, Department of Genetics, Harvard Medical School)
- Vivek Dharwal (Professor, Department of Biochemistry, Panjab University)
- Alfred Nijkerk (Chief Executive Officer, UbiQ)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What are PARP inhibitors? Answer:
PARP inhibitors belong to a class of novel pharmacological inhibitors targeting the enzyme PARP (poly ADP ribose polymerase). These inhibitors are primarily developed for indications, including the treatment of heritable cancers.
Question 2: How big is the PARP inhibitors market? Answer:
The PARP inhibitors market size is estimated to be worth $8 billion in 2030.
Question 3: What is the projected market growth of the PARP inhibitors market? Answer:
The PARP inhibitors market is expected to grow at compounded annual growth rate (CAGR) of 18% during the forecast period 2019 – 2030.
Question 4: Who are the leading companies in the PARP inhibitors market? Answer:
Examples of key companies engaged in PARP inhibitors market (which have also been profiled in this market report; the complete list of companies is available in the full report) include AbbVie, AstraZeneca, BeiGene, Clovis Oncology, GlaxoSmithKline, Pfizer and AtlasMedx.
Question 5: How many articles related to PARP inhibitors have been published over the last few years? Answer:
Since 2017, close to 700 articles related to PARP inhibitors have been published, indicating the ongoing research in the industry.
Question 6: Which region emerged as the hub for companies engaged in the PARP inhibitors market? Answer:
North America emerged as the hub for players engaged in the development of PARP inhibitors, with close to 60% of the companies established in the region.